PATENT CLAIM ANALYSIS

Application Number: 15950413
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-12
Patent Classification: ["514", "007200"]

Abstract:
Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.

Claim (Index 50):
A method of reducing mortality and morbidity after myocardial infarction in a mammal comprising administering to the mammal a peptide of the formula:\n des Ala 38 -(Lys 40 (palmitoyl))exendin-4(1-39)-NH 2 (SEQ ID NO:109), the free acid thereof, or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce mortality and morbidity after myocardial infarction.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.41304
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['10529858', '14735738', '13642349', '15381993', '14864540']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7271629777401314
- 35 USC 102 Novelty (BERT): 0.531797724894762
- Combined Prediction Score: 0.7076264524555944
- Mean Citation Score: 300.797012
- Max Citation Score: 331.3519
- Similarity Product: 215.05897278189656

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test